Edition:
United States

Genocea Biosciences Inc (GNCA.OQ)

GNCA.OQ on NASDAQ Stock Exchange Global Market

5.59USD
24 Mar 2017
Change (% chg)

-- (--)
Prev Close
$5.59
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
34,410
52-wk High
$8.04
52-wk Low
$3.29

GNCA.OQ

Chart for GNCA.OQ

About

Genocea Biosciences, Inc. is a clinical-stage biotechnology company. The Company is a biopharmaceutical company that discovers and develops vaccines and immunotherapies. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or... (more)

Overall

Beta: --
Market Cap(Mil.): $159.31
Shares Outstanding(Mil.): 28.50
Dividend: --
Yield (%): --

Financials

  GNCA.OQ Industry Sector
P/E (TTM): -- 47.98 29.94
EPS (TTM): -1.75 -- --
ROI: -59.83 -2.56 13.01
ROE: -73.33 5.14 14.16

BRIEF-Genocea reports Q4 loss per share $0.56

* Genocea reports fourth quarter and year-end 2016 financial results

Feb 16 2017

BRIEF-Genocea reports Q3 loss per share $0.45

* Genocea biosciences -expects that its existing cash, cash equivalents are sufficient to support its operating expenses and capex into q1 of 2018

Nov 03 2016

BRIEF-Genocea's Genital Herpes Immunotherapy GEN-003 demonstrates significant reduction of viral shedding in phase 2b clinical trial

* Genocea's Genital Herpes Immunotherapy GEN003 demonstrates significant reduction of viral shedding in phase 2b clinical trial

Sep 29 2016

More From Around the Web

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF73.35 -0.40
Pfizer Inc. (PFE.N) $34.00 -0.29
Merck & Co., Inc. (MRK.N) $63.18 -0.10
Sanofi SA (SASY.PA) €82.59 -0.28
AstraZeneca plc (AZN.L) 4,908.60 -19.90
GlaxoSmithKline plc (GSK.L) 1,668.50 -2.00
Vical Incorporated (VICL.OQ) $2.19 --

Earnings vs. Estimates